Challenges in Alzheimer Disease Drug Discovery and Development: The Role of Modeling, Simulation and Open Data.

Clicks: 470
ID: 84448
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1 of 11 articles by views in clinical pharmacology and therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Alzheimer disease (AD) is the leading cause of dementia worldwide. With 35 million people over 60 years of age with dementia, there is an urgent need to develop new treatments for AD. To streamline this process, it is imperative to apply insights and learnings from past failures to future drug development programs. In the present work, we focus on how modeling and simulation (M&S) tools can leverage open data to address drug development challenges in AD.
Reference Key
conrado2020challengesclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Conrado, Daniela J;Duvvuri, Sridhar;Geerts, Hugo;Burton, Jackson;Biesdorf, Carla;Ahamadi, Malidi;Macha, Sreeraj;Hather, Gregory;Morales, Juan Francisco;Podichetty, Jagdeep;Nicholas, Timothy;Stephenson, Diane;Trame, Mirjam;Romero, Klaus;Corrigan, Brian;, ;
Journal clinical pharmacology and therapeutics
Year 2020
DOI
10.1002/cpt.1782
URL
Keywords
Simulation alzheimer disease modeling open data open science challenges drug discovery drug development novel technologies

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.